重组链激酶或尿激酶联合替罗非班治疗老年急性心肌梗死患者的临床观察被引量：8

Clinical Observation on Recombinant Chain Kinase or Urokinase combined Tirophan Treatment for Elderly Patients with Acute Myocardial Infarction

在线阅读下载PDF

导出

摘要目的观察重组链激酶与尿激酶分别联合替罗非班治疗老年急性心肌梗死(AMI)患者的临床效果。方法选取164例老年AMI患者为受试对象,按照入院顺序随机分为实验组和对照组各82例,分别予以重组链激酶联合替罗非班治疗、尿激酶联合替罗非班治疗。观察并记录两组患者溶栓后0.5 h、1 h、1.5 h、2 h冠脉再通情况,记录治疗前、治疗后凝血功能指标,凝血酶原时间(PT)、活化部分凝血活酶时间(aPTT)、凝血酶时间(TT)、纤维蛋白原(Fbg)]变化。结果实验组患者溶栓后1 h、1.5 h、2 h冠脉再通率均明显高于对照组;治疗后5 h,两组患者PT、aPTT、TT较治疗前明显延长,血清Fbg水平均较治疗前明显降低,实验组患者各项指标变化幅度更大(P均<0.05)。结论重组链激酶联合替罗非班应用于老年AMI患者,较尿激酶联合替罗非班抗凝效果更佳,可提高冠脉再通率,改善凝血功能。

作者原斌 HUAN Bin(depanment of cardiology,Lanzhou military region general hospital anning branch,Lanzhou,730070,China)

机构地区兰州军区总医院安宁分院心内科

出处《血栓与止血学》 2019年第1期65-66,68,共3页 Chinese Journal of Thrombosis and Hemostasis

关键词重组链激酶尿激酶替罗非班急性心肌梗死

分类号 R542.2+2 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献6

1王喜福,杨铎,曾玉杰.青年与老年急性心肌梗死患者血浆炎性因子的对比分析[J].心肺血管病杂志,2015,34(6):441-443. 被引量：14
2傅慎文,胡宪清,钟鸣,唐彪,毛燕艳.直接经皮冠状动脉内介入治疗老年急性心肌梗死患者疗效和安全性的研究[J].中华老年医学杂志,2015,34(2):126-128. 被引量：15
3沈卫峰,张奇,张瑞岩.2015年急性ST段抬高型心肌梗死诊断和治疗指南解析[J].国际心血管病杂志,2015,42(4):217-219. 被引量：257
4陈泽江,黄修献.阿替普酶与尿激酶溶栓治疗急性心肌梗死疗效观察[J].现代中西医结合杂志,2016,25(10):1087-1089. 被引量：36
5李韶南,刘震,黄慧芳,陈平安,雷晓明.高剂量他汀对急性心肌梗死患者血小板功能及心室重构的影响[J].中国医师杂志,2015,17(4):519-523. 被引量：8
6戴树人,李芝峰,廖荣宏,李晓丽,高崇瀚,杨爽,陈紫君.替罗非班联合瑞替普酶在ST段抬高性急性心肌梗死中的疗效观察[J].重庆医学,2014,43(21):2720-2721. 被引量：25

二级参考文献58

1陈灏珠,林果为.实用内科学[M].13版.北京:人民卫生出版社,2009:919.
2陈新谦,金有豫,汤光.新编药物学[M].17版.北京:人民卫生出版社,2011:3465.
3Steg PG,James management of presenting with SK,Atar D, et al. ESC Guidelines for the acute myocardial infarction in patients ST-segment elevation[J]. Eur Heart J,2012,33(20):2569-2619.
4American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions. 2013 AC- CF/AHA guideline for the management of ST-elevation myocardial infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2013,61(4) :e78-140.
5Ottani F, Bresciani B, La Vecchia L, et al. Combination therapy for acute myocardial infarction with glycoprotein IIb/IIIa inhibitors and fibrinolysis[J].ItalHeart J Suppl, 2002,3(5):544-554.
6Kunadian V, Gibson CM. Thrombolytics and myocardial infarction[J ]. Cardiovasc Ther, 2012,30 ( 2 ): e81-88.
7Zoni A, Knoll P, Gherli T. Microvascular obstruction after successful fibrinolytic therapy in acute myocardial infarc- tion. Comparison of reteplase vs reteplase+ abciximab: A cardiovascular magnetic resonance study[J]. Heart Int, 2006,2(1) :54.
8Diaz JF, Cardenal R, Gomez-Manchero A, et al. Safety and efficiency of tirofiban as adjunctive therapy for patients with ST-elevation myocardial infarction: a comparison versus placebo and abciximab[J]. Cardiovasc Hematol A-gents Med Chem,2011,9(3) :147-153.
9Abbate A, Kontos MC, Biondi Zoccai GG. No-reflow :the next chalIenge in treatment of ST-elevation acute myocardial infarction [J]. Eur Heart J,2008, 29(5) : 1795-1797.
10Rodes Cabau J, Tardif JC, Cossette M, et al. Acute effects of sta- tin therapy on coronary atherosclerosis following an acute coronary syndrome [J]. Am J Cardiol, 2009, 104(6) : 750-757.